

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Review of TA274; Ranibizumab for treating diabetic macular oedema

Final recommendation post consultation
The guidance should be transferred to the 'static guidance list'.

1. Background

This guidance was issued in April 2013.

At the GE meeting of 10 February 2015 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance list'.

3. Rationale for selecting this proposal

The new evidence identified from the literature searches and registered trials does not indicate that a review of the recommendations in technology appraisal 274 is needed, and the marketing authorisation and price has not changed. It is therefore proposed that technology appraisal guidance 274 is transferred to the 'static guidance list'.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: Royal College of Nursing</p> <p>Response to proposal: No comment</p> <p>The Royal College of Nursing invited members who expressed interest in this area of health to comment on the review proposal of the above consultation.</p> <p>The feedback received suggests that there are no additional comments to make on behalf of the RCN.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted. No action required.</p>
<p>Respondent: Royal College of Pathologists</p> <p>Response to proposal: No comment</p> <p>The Royal College of Pathologists does not have any comment or evidence to provide for this review.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted. No action required.</p>
<p>Respondent: Novartis</p> <p>Response to proposal: Agree</p> <p>we agree with NICE that there is little relevant new evidence that would lead to changes to the existing recommendations made in TA274. Therefore we welcome the decision from NICE to move this proposed review to the static list.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted. No action required.</p>

Paper signed off by: Elisabeth George, 25 03 15

Contributors to this paper:

Technical Lead: Caroline Hall

Project Manager: Andrew Kenyon